Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from leguminosae
Reexamination Certificate
2006-07-18
2006-07-18
Tate, Christopher R. (Department: 1655)
Drug, bio-affecting and body treating compositions
Plant material or plant extract of undetermined constitution...
Containing or obtained from leguminosae
C424S725000, C424S777000, C514S893000, C514S894000
Reexamination Certificate
active
07078064
ABSTRACT:
The invention relates generally to compositions comprising antioxidants useful for reducing oxidative stress and lipid peroxidation, and treating chronic liver disease, chronic hepatitis C virus infection and non-alcoholic steatohepatitis. In particular, the invention relates to the preparation and oral administration of compositions comprising glycyrrhizin,schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol. The invention also relates to the preparation and parenteral administration of compositions comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, preferably by infusion or intravenous injection. The invention further relates to methods of using the antioxidants, oral compositions and parenteral compositions.
REFERENCES:
patent: 5770217 (1998-06-01), Kutilek et al.
patent: 6455078 (2002-09-01), Wu
Abe Y. et al. Effectiveness of interferon, glycyrrhizin combination therapy in patients with chronic hepatitis C.Nippon Rinsho. 1994; 52(7):1817-22 (in Japanese with English Abstract).
Arase Y. et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients.Cancer1997; 79(8):1494-500.
Barbaro G. et al Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease.Am J Gastroenterol. 1996; 91(12):2569-73.
Berkson B.M. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories.Med Klin. 1999; 94 Suppl 3:84-9.
Boigk G. et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats.Hepatology1997; 26(3):643-649.
Boya P. et al. Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C.J Hepatol. 1999; 31(5):808-14.
Bustamante J. et al., Alpha-lipoic acid in liver metabolism and disease.Free Radic Biol Med. 1998; 24(6):1023-39.
Buzzelli G. et al. A pilot study on the liver protective effect of silybin phosphatidylcholine complex (1dB1016) in chronic active hepatitis.Int J Clin Pharmacol Ther Toxicol. 1993; 31:456-460.
Chrobot A.M. et al. Antioxidant defense in children with chronic viral hepatitis B and C.Med Sci Monit2000; 6(4): 713-8.
Cook G.C. et al. Results of a controlled clinical trial of glutathione in cases of hepatic cirrhosis.Gut1965; 6(5):472-6.
Dehmlow C. et al. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin.Hepatology1996; 23:749-754.
Eberhardt G. et al. Controlled study of the therapeutic effect of B vitamins and an anabolic steroid in chronic hepatitis.Disch Med Wochenschr. 1975; 100(41):2074-82 (in German with English abstract).
Feher I. et al. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases.Orv Hetil. 1989; 130:2723-2727 (in Hungarian with English abstract).
Ferenci P. et al., Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.J Hepatol. 1989; 9:105-113.
Fujisawa Y. et al. Glycyrrhizin inhibits the lytic pathway of complement—possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis.Microbiol Immunol. 2000; 44(9):799-804.
Gagliardi B. et al., Results of a double blind study on the effect of silymarin in the treatment ofacute viral hepatitis, carried out at two medical centers.Med Klin. 1978; 73:1060-1065.
Gut J. et al. Mechanisms of halothane toxicity: novel insights.Pharmacol Ther. 1993; 58(2): 133-55.
Hargreaves R.J. et al. Studies on the effects of L-ascorbic acid on acetaminophen-induced hepatotoxicity. II. Anin vivoassessment in mice of the protection afforded by various dosage forms of ascorbate.Toxicol Appl Pharmacol. 1982; 64(3):380-92.
Hill D.B. et al. Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro.Clin Biochem. 1999; 32(7):563-70.
Houglum K. et al. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C.Gastroenterology1997; 113(4): 1069-73.
Hruby K. et al. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin.Hum Toxicol. 1983; 2:183-195.
Iimuro Y. et al. The glutathione precursor L-2-oxothiazolidine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat.Hepatology2000; 31(2): 391-8.
Iino S. et al. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis.Hepatol Res. 2001; 19(1):31-40.
Kang S.Y. et al. Hepatoprotective activity of scopoletin, a constituent of Solarium lyratum.Arch Pharm Res. 1998; 21(6): 718-22.
Khodykin A.V. The efficacy of a diet enriched by lipotropic factors, and vitamin C and vitamin B-complex in patients with chronic hepatitis.Vopr Pitan. 1958; 17(2):19-29 (in Russian with English summary).
Komar VI. Application of vitamin B12 in combined treatment of viral hepatitis.Vopr Pitan. 1982; (1):26-9 (in Russian with English summary).
Li X.J., Scavenging effects on active oxygen radicals by schizandrins with different structures and configurations.Free Radic Biol Med. 1990; 9(2):99-104.
Liu G.T. Pharmacological actions and clinical use of fructus schizandrae.Chin Med J. (Engl) 1989;102(10):740-9.
Liu K.T., Pharmacological properties of Dibenzo[a,c]cyclooctene derivatives isolated from Fructus Schisandra Chinensis III. Inhibitory effects on carbon tetrachloride-induced lipid peroxidation, metabolism and covalent binding of carbon tetrachloride to lipids.Chem Biol Interact. 1982; 41(1):39-47.
Liu S.L. et al. Vitamin E therapy of acute CC14-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding.Hepatology1995; 22(5):1474-81.
Loguercio C. et al. Alpha-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to interferon therapy?J Hepatol. 1998; 28(3):390-5.
Look M.P. et al. Interferon/antioxidant combination therapy for chronic hepatitis C—a controlled pilot trial.Antiviral Res. 1999; 43(2):113-22.
Lu H. et al., Effect of dibenzo[a,c]cyclooctene lignans isolated fromFructus schizandraeon lipid peroxidation and anti-oxidative enzyme activity.Chem Biol Interact. 1991; 78(1):77-84.
Luper S. A review of plants used in the treatment of liver disease: Part 1.Altern Med Rev. 1998; 3:410-421.
Magliulo E. et al. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres.Med Klin. Jul. 14, 1978; 73(28-29): 1060-5 (in German with English summary).
Mahmood S. et al. Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C.Free Radic Res. 2003; 37(7):781-5.
Marshall A.W. et al. Treatment of alcohol-related liver disease with thioctic acid: a six month randomized double-blind trial.Gut1982; 23(12):1088-93.
Matsuo K. et al. Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma.Leuk Lymphoma2001; 41(1-2): 191-5.
McPartland J.M. Viral hepatitis treated withPhyllanthus amarusand milk thistle (Silybum marianum).Complementary Medicine International1996; Mar./Apr.: 40-42.
Meydani S.N. et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial.JAMA1997; 277(17): 1380-6.
Mitra A. et al. Effect of ascorbic acid esters on hepatic glutathione levels in mice treated with a hepatotoxic dose of acetaminophen.J Biochem Toxicol. 1991; 6(2):93-100.
Moller E. et al. A contribution to the treatment of chronic liver diseasesMed Klin. 1976; 71(43):1831-5.
Morazzoni P. et al., Comparative pharmacokinetics of silipide and silymarin in rats.Eur J Drug Metab Pharmacokinet. 1993; 18:2
Jones Day
Tate Christopher R.
LandOfFree
Compositions and methods useful for treating and preventing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods useful for treating and preventing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods useful for treating and preventing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3582642